Pancreatic cancer (PC) is a highly invasive tumor with early metastasis and poor prognosis, yet the mechanisms for tumor progression have not been fully elucidated. Emerging evidence indicates that microRNA-331-3p (miR-331-3p) plays an important role in the progression of diverse human cancers. Here, we found that miR-331-3p was significantly upregulated in tumor specimens of PC patients and PC cell lines. Functional studies showed that downregulation of miR-331-3p inhibited PC cell proliferation and epithelial-mesenchymal transition (EMT)-mediated metastasis in vitro. Furthermore, suppression of tumorigenicity 7 like (ST7L) was identified as a novel target gene of miR-331-3p. Tumor promotion effects of miR-331-3p were partially reversed by ST7L re-expression. In addition, miR-331-3p antagomir suppressed PC tumor growth and metastasis via upregulation of ST7L in xenograft mice. In summary, these results demonstrate that miR-331-3p is a tumorpromoting microRNA (miRNA) in PC cells and a promising biomarker for PC.
Introduction
Pancreatic cancer (PC) is an extremely aggressive malignant tumor, largely due to the lack of early diagnostic markers. PC is the fourth leading type of cancer death, and it is estimated that more than 53 670 new cases will be diagnosed in 2017 in the USA (1) . Despite developments in detection and therapeutic management of PC, the 5-year survival rate for patients after diagnosis is a dismal 4% (2) . Surgical resection at present still offers the only effective cure of early PC, but unfortunately, more than 80% PC patients were diagnosed with advanced unresectable disease (3) . Moreover, high metastasis rates and chemotherapy resistance make PC one of the most lethal cancers with high mortality and poor prognosis. Hence, there is an urgent need to discover the underlying mechanisms that contribute to development and progression of PC.
MicroRNAs (miRNAs) are endogenous small non-coding RNAs (approximately 22 nt) that regulate gene expression by targeting the 3′-untranslated region (UTR) of messenger RNAs (mRNAs) to induce their degradation or translational repression (4, 5) . It has been reported that aberrant miRNAs expression is involved in a variety of biological and pathologic processes, including proliferation, cell apoptosis, invasion and metastasis (6) (7) (8) . Increasing evidences suggest that miRNAs are pivotal regulators of tumor progression, as well as molecular markers for diagnosis and prognosis in human cancer (9) (10) (11) (12) . It has been shown that miR-331-3p facilitates proliferation and metastasis by promoting epithelial-mesenchymal transition (EMT) of hepatocellular carcinoma (HCC) by targeting 'PH Domain and leucine-Rich Repeat Protein Phosphatase' (13) (PMID: 24825302). Recently, another group reports that elevated expression of miR-331-3p accelerates the proliferation of HCC cells (14) (PMID: 26497554). In addition, the serum level of miR-331-3p is elevated in HCC patients, which can serve as a diagnostic and prognostic marker for HCC (15) (PMID: 25903466). Accumulating evidence supports that miR-331-3p is dysregulated in multiple cancers (16) (17) (18) (19) (20) (PMID: 23817697; 20510161; 25750939; 24142150; 26718987). However, the pathobiological functions of miR-331-3p in PC remain elusive.
In this study, we found that miR-331-3p was upregulated in the clinical specimens of PC and PC cell lines and analyzed its potential clinical significance. Ectopic expression of miR-331-3p promoted PC cell proliferation and EMT-mediated metastasis. Additionally, we identified suppression of tumorigenicity 7 like (ST7L) as a target gene of miR-331-3p. ST7L, identified by its similarity to the ST7 tumor suppressor gene located at the chromosome 7q31 region, participates in the β-catenin pathway and plays a tumor-suppressive role in many cancers (21) (22) (23) . We further revealed that reduced miR-331-3p expression suppressed the progression of PC in vivo. Our research provided new insight into the oncogenic role of miR-331-3p.
Materials and methods

Clinical specimens
The 17 pairs of PC and corresponding paracancerous normal tissue samples were obtained from patients who had undergone surgical resection without preoperative chemoradiotherapy in the Central Hospital of Wuhan and Renmin Hospital of Wuhan University. These tissue specimens were snap-frozen in liquid nitrogen immediately and stored at −80°C. Admission plasma of 44 PC patients who had not received chemoradiotherapy and control plasma samples from 23 healthy individuals was recruited from the same two hospitals. All peripheral plasma samples were collected in EDTA tubes and processed within 4 h by centrifuging at 1000g for 15 min at 4°C. The plasma was then gently transferred to a fresh RNase/DNase-free 1.5 ml EP tube (Axygen, Union City, CA) and stored at −80°C. This study was approved by the Ethical and Scientific Committees of the Tongren Hospital of Wuhan University, and all human subject research was performed in accordance with institutional, national and Declaration of Helsinki requirements. Informed consent was obtained from all study participants, and samples were collected from 2016 to 2017.
Cell lines and cell culture
The human PC cell lines PANC-1, MIAPaCa-2, AsPC-1, BxPC-3, SW1990 and human embryonic kidney (HEK) 293T cells were purchased from the American Type Culture Collection (ATCC). The human normal pancreatic ductal epithelial cell line, H6C7 was provided by the Cell Bank of the Chinese Academy of Sciences (Shanghai, China). We confirm the authentication of all cell lines used-the full policy and requirements are available in the instructions to authors. PANC-1, MIAPaCa-2 and HEK-293T cells were cultured in Dulbecco's modified Eagle medium (DMEM, Gibco, Carlsbad, CA). AsPC-1, BxPC-3 and SW1990 were cultured in RPMI-1640 medium (Gibco). All of the media were supplemented with 10% fetal bovine serum (Gibco), 100 μg/ml streptomycin and 100 IU/ml penicillin (Thermo Fisher Scientific, Rockford, IL). Cells were incubated in a humidified incubator at 37°C with 5% CO 2 .
miRNA microarray
To prepare the miRNA microarray, we collected five plasma specimens from PC patients and five from healthy individuals and pooled as one PC sample and one normal sample (100 μl of each specimens). All 500 μl plasma was used to extract total RNAs. The amounts of total RNAs extracted from each sample pool were determined by Nanodrop ND-2000 (Thermo Scientific): 32 ng for the PC sample pool and 30 ng for normal sample pool. The total RNAs were sent to Shanghai Biotechnology Corporation (Shanghai, China), where the amounts and quality of the total RNAs were affirmed by an Agilent Bioanalyzer 2100 (Agilent Technologies). Equal amounts of total RNAs from each pool (20.0 ng) were dephosphorylated, denaturated and then labeled with Cyanine-3-CTP. After purification, the labeled RNAs were hybridized onto the Agilent SurePrint Human miRNA microarrays. After washing, the arrays were scanned with the Agilent Scanner G2505C (Agilent Technologies). Feature Extraction software (version10.7.1.1, Agilent Technologies) was used to analyze array images to get raw data. Data analysis was performed by GeneSpringGX software 11.0 (Agilent Technologies).
miRNA in situ hybridization
All PC tissues were embedded in paraffin, and the tissue microarray was synthesized by Shanghai Outdo Biotech (Shanghai, China). In situ hybridization was performed with a 5′-and 3′-DIG-labeled miR-331-3p detection probe (Exiqon, Denmark). Staining was evaluated using a semiquantitative immunoreactivity scoring (IRS) system. Staining intensity was scored as 0 = no staining; 1 = weak staining; 2 = moderate staining; 3 = strong staining. Percentage of positively stained cells was scored as 1 = 10-25%; 2 = 26-50%; 3 = 51-75%; 4 = 76-100%. If less than 10% of the cells were stained, a score of 0 was given. IRS values ranging from 0 to 12 were calculated as the staining intensity score (0 to 3) multiplied by the score (0 to 4) of the percentage of positively stained cells. Specimens with IRS values ≤6 were classified into the miR-331-3p low-expression group and those with IRS values >6 into the miR-331-3p high-expression group. Immunohistochemistry analyses performed in the tissue microarray were also based upon the IRS system.
RNA extraction and qRT-PCR
Total RNA from tissues and cell lines was isolated using the TRIzol reagent (Invitrogen, Carlsbad, CA). Plasma miRNA from PC patients and healthy subjects was extracted from a mirVana PARIS kit (Ambion, Carlsbad, CA) according to the manufacturer's instructions. The plasma miRNA and total RNA reverse transcription were performed using the Reverse Transcription kit (TOYOBO, Japan). The reverse transcription products were subsequently analyzed using UltraSYBR Mixture (ComWin Biotech, China) on an ABI StepOne Plus qPCR system (Applied Biosystems). The primers used were as follows: ST7L sense (5′-GCAGAATATAGGAGATACACTTGGG-3′) and antisense (5′-TCTGCATAACTGTGTCTGAAGGACG-3′). Primers of miR-331-3p and U6 were obtained from RiboBio Corporation (Guangzhou, China). miRNA and mRNA expression levels were normalized with U6 snRNA as a reference and expressed as 2 -[CT (miRNA) − CT (U6)] , with CT denoting the threshold cycle. 
Abbreviations
Cell transfection and vector construction
Oligonucleotides including hsa-miR-331-3p mimics (sense: 5′-GCCCCUGGG CCUAUCCUAGAA-3′; antisense: 5′-CUAGGAUAGGCCCAGGGGCUU-3′), hsa-miR-331-3p inhibitor (5′-UUCUAGGAUAGGCCCAGGGGC-3′), hsa-miR mimics negative control (sense: 5′-UUCUCCGAACGUGUCACGUTT-3′; antisense: 5′-ACGUGACACGUUCGGAGAATT-3′) and hsa-miR inhibitor negative control (5′-CAGUACUUUUGUGUAGUACAA-3′) were synthesized from Genepharma (Shanghai, China). PANC-1 and MIAPaCa-2 cells were transiently transfected using Lipofectamine® LTX with Plus reagent (Invitrogen) at a final concentration of 100 nM according to the manufacturer's instructions. The ST7L expression plasmid was constructed by inserting the ST7L open reading frame sequence into the pCMV6 vector (OriGene).
CFSE labeling assay
Cell proliferation was measured using carboxyfluorescein diacetate succinimidyl ester (CFSE; Invitrogen) labeling method that monitors distinct generations of proliferating cells by dye dilution. PANC-1 and MIAPaCa-2 cells were suspended in phosphate-buffered saline with 5 μM CFSE staining solution and then incubated at 37°C for 20 min, protected from light. Cells were washed twice with DMEM complete medium after uniform cell labeling. Labeled cells were plated into 12-well plates and cultured in DMEM medium. Next, cells were transfected with 100 nM oligonucleotides and cultured for 48 h before flow cytometry on a FACS AriaⅡ flow cytometer (Becton-Dickinson, BD Biosciences, Franklin Lakes, NJ). The cell proliferation index (PI) was subsequently calculated.
Colony formation assay
Cells were cultured for 24 h post transfection and placed in six-well plates (600 cells/well) in triplicate, incubated at 37°C in DMEM complete medium for 2 weeks. Cells were fixed with methanol, stained with 0.1% crystal violet and dried. The visible colonies containing >50 cells were counted.
Wound-healing assay
Cells were seeded in 12-well plates and then transfected with different oligonucleotides or plasmids when cell confluence approach to 70%. Cells were incubated in a humidified incubator at 37°C for 24 h. A 200 μl pipette tip was used to scratch in the confluent monolayers. To remove the detached cells, plates were washed twice by phosphate-buffered saline. Cells were then cultured in medium without fetal bovine serum at 37°C and photographed at 0 and 24 h under an inverted phase contrast microscope. Three random fields were captured and measured for each well.
Transwell assay
Cell migration was carried out using Transwell cell migration plates (Corning), and cell invasion assay was performed in Matrigel invasion chambers (BD Biosciences, NJ). Cells (5 × 10 4 ) were seeded into the upper chambers with 200 μl serum-free medium, and the lower chambers were filled with culture medium containing 10% fetal bovine serum. After incubation for 12 h (in migration assay without precoated matrigel) or 24 h (in invasion assay with Matrigel coating), cells that failed to migrate or invade through the membrane were removed gently with cotton swabs, while the migrated or invaded cells on the bottom were fixed with 4% formaldehyde for 20 min and stained with 0.1% crystal violet for 30 min before photographed under a microscope (OLYMPUScx31, TOKYO, Japan). Five visual fields were randomly chosen and imaged.
Luciferase reporter assay
The wild-type (wt) or mutant (mt) 3′-UTR sequences of ST7L were inserted into the downstream of reporter gene between the XbaI and Not I (New England Biolabs, Ipswich, MA) sites of pRL-TK vector (Promega, Madison, WI), and the positive clones were confirmed by Sanger DNA sequencing. PANC-1 cells were seeded in 96-well culture plates (1 × 10 4 cells/ well) and cotransfected with pRL-TK-ST7L-3′-UTR or pRL-TK-ST7L-3′-UTR mutant vectors (10 ng) and 100 ng of pGL3-Control (Promega) along with 10 pmol miR-331-3p mimic or miR-331-3p inhibitor in triplicate using Lipofectamine® LTX and Plus reagent (Invitrogen) according to the manufacturer's instructions. Luciferase activities of firefly and Renilla luciferases were measured 48 h post transfection using a Dual-Glo Luciferase Reporter Assay kit (Promega).
Western blotting
The total protein of cultured cells was extracted using RIPA buffer (Beyotime, Shanghai, China) and quantified with a BCA protein assay kit (Thermo Fisher Scientific). Equal amounts of protein extracts from each sample were separated by 10% SDS-PAGE and transferred onto nitrocellulose membranes. The membranes were blocked with 5% non-fat dry milk in Tris-buffered saline with Tween-20 and incubated with primary antibodies against ST7L (1:1000, Sigma), E-cadherin (1:1000, BD Biosciences), N-cadherin (1:1000, CST, Danvers, MA), vimentin (1:1000, CST) and β-actin (1:1000, Santa Cruz, Delaware, CA) overnight at 4°C. The membranes were incubated with secondary antibody (1:10,000, Santa Cruz) later. Protein bands were detected using the ECL chemiluminescent kit (Thermo Fisher Scientific) and analyzed by the ChemiDoc XRS+ imaging system (Bio-Rad).
Xenograft mouse model
Five-week-old female BALB/c nude mice were purchased from Beijing Vital River Laboratory Animal Technology Co., Ltd. (Beijing, China) and randomly assigned to two groups (n = 5 per group). After 6 days of acclimatization, each nude mice was injected subcutaneously at the flank with 5 × 10 6 PANC-1 cells suspended in 100 μl phosphate-buffered salinecontaining 25% Matrigel. When the tumor volume reached approximately 60 mm 3 , tumors of nude mice were injected with miR-331-3p antagomir or antagomir control synthesized by the GenePharma Company. miR-331-3p antagomir or antagomir control (20 μl, 250 μM) was injected into the tumors at multiple sites every 5 days for three times, respectively. Tumor volume was measured every 5 days and calculated using the formula tumor volume = (length × width 2 )/2. Tumor weight was measured and recorded in grams. Animals were sacrificed on the 25th day after injection. Tumors were collected, and the expressions of miR-331-3p and immunohistochemistry were analyzed. All the animal experiments were conducted under a protocol approved by the Institutional Animal Care and Use Committee at Wuhan University.
Immunohistochemistry
Tumor sections were analyzed by immunohistochemical staining of Ki-67, E-cadherin, N-cadherin and Vimentin. Tumor tissues were fixed with 4% paraformaldehyde, embedded in paraffin and cut into sections of about 4 macrons. Sections were subsequently deparaffinized, rehydrated and rinsed before antigen retrieval and endogenous peroxidase blocking. Immunohistochemistry analyses were performed in the presence of primary antibodies against ST7L (1:150, Sigma), Ki-67 (1:150, TDY Biotech, China), E-cadherin (1:150, BD Biosciences), N-cadherin (1:150, CST) and vimentin (1:150, CST) together with HRP-conjugated secondary antibodies. Standard DAB method (ZSGB-Bio, China) was employed to detect the staining.
Statistical analysis
Statistical analysis was performed using GraphPad Prism software. Comparison between two groups was evaluated with Student's t-test. Comparison among three or more groups was analyzed by one-way analysis of variance. Data were presented as the mean ± SD. P values <0.05 were deemed statistically significant.
Results
miR-331-3p is upregulated in PC
To investigate the roles of miRNAs in PC progression, we first screened differentially expressed miRNAs between the plasma of five PC patients and that of five healthy control subjects. According to the miRNA microarray analysis ( Figure 1A ), there were 275 differentially expressed miRNAs, including 196 upregulated miRNAs and 79 downregulated miRNAs in PC compared with the control. We analyzed the expression of eight dysregulated miRNAs in PC cell lines (Supplementary Figure 1, available at Carcinogenesis Online). We found that miR-331-3p was the only one upregulated miRNA in all five PC cell lines compared with a non-cancerous cell line. Given that the role of miR-331-3p in PC is unclear, we focus on this miRNA for further analysis. Using qRT-PCR, we analyzed the plasma levels of miR-331-3p in each patient whose plasma had been used for the microarray analysis: the plasma levels of miR-331-3p in 5 PC patients were significantly higher than that in the healthy individuals (Supplementary Figure 2 , available at Carcinogenesis Online). When additional samples (a total of 44 PC and 23 control subjects) were analyzed, similar results were observed ( Figure 1B) . Next, we analyzed miR-331-3p expression level in the plasma of 24 PC patients before and after surgical removal of the tumors. The miR-331-3p level in the plasma was significantly reduced after the operation ( Figure 1C ). In addition, we analyzed the expression levels of miR-331-3p in 17 pairs of PC tissues and adjacent non-cancerous tissues. The expression of miR-331-3p was observably higher in cancer tissues than in the non-cancerous tissues ( Figure 1D ). Results showed that 82% (14/17) of patients exhibited higher expression of miR-331-3p and 18% (3/17) of patients exhibited lower expression. To further detect the increased level of miR-331-3p in PC clinical specimens, we applied in situ hybridization with a 3′-and 5′-DIG-labeled miR-331-3p probe using a PC tissue microarray contained 20 pairs of PC tissues and adjacent noncancerous tissues. The in situ hybridization results were evaluated using an IRS analysis system, and as shown in Figure 1E , the expression level of miR-331-3p was higher in PC tissues than in adjacent tissues. Taken together, these data revealed that the expression level of miR-331-3p was elevated in PC.
Furthermore, we examined the relationship between the plasma miR-331-3p expression and clinical parameters. Patients were divided into two groups based on levels of miR-331-3p expression (high and low). As shown in Table 1 , high miR-331-3p expression was associated with advanced PC stage and distant metastasis, suggesting that miR-331-3p promotes PC progression.
Downregulation of miR-331-3p inhibits PC cell proliferation and EMT-mediated metastasis in vitro
Having observed miR-331-3p upregulation in PC, we went on functionally characterizing miR-331-3p by studying its impact on PC cell proliferation and invasion. PANC-1 and MIAPaCa-2 cells were transfected with the miR-331-3p inhibitor or an inhibitor control. Cell proliferation was determined using the CFSE labeling method. Both PANC-1 and MIAPaCa-2 cells transfected with the miR-331-3p inhibitor had a decrease in PI compared with the control (Figure 2A-D) . A colony formation experiment illustrated that the propagation ability of these two cell lines transfected with the miR-331-3p inhibitor was significantly decreased in comparison with the control (Figure 2E ). In addition, wound healing and transwell migration assays showed that reduced levels of miR-331-3p weakened the capacity of cell migration in both PANC-1 and MIAPaCa-2 cells (Figure 2F and G) . Meanwhile, the Matrigel invasion assay revealed that decreased expression of miR-331-3p significantly reduced the capacity of cell invasion compared with the control (Figure 2H ). To examine whether downregulation of miR-331-3p inhibited EMT-mediated metastasis, we performed western blotting to detect E-cadherin 
MiR-331-3p directly targets ST7L in PC
In order to characterize the mechanism by which miR-331-3p regulates the functions of PC cells, we tried to identify candidate target genes of miR-331-3p using TargetScan (version 7.0). Among numerous predicted targets of miR-331-3p, ST7L was selected for further studies. The putative binding site for miR-331-3p in the 3′-UTR of ST7L was showed as Figure 3A . First, qRT-PCR showed that miR-331-3p was expressed at a higher level in five PC cell lines than in a human normal pancreatic ductal epithelial cell line ( Figure 3B ). Inversely, ST7L mRNA levels were significantly reduced in five PC cells lines ( Figure 3C ). Second, overexpression of miR-331-3p decreased the mRNA and protein levels of ST7L, whereas inhibition of miR-331-3p elevated both the mRNA and protein levels of ST7L in PC cells ( Figure 3D and E). The western blots for ST7L were presented in Supplementary Figure 3 , available at Carcinogenesis Online. Third, a dual-luciferase reporter assay showed that overexpression of miR-331-3p significantly suppressed the firefly luciferase reporter upstream of the wild-type ST7L 3′-UTR but not the mutant 3′-UTR ( Figure 3F) ; inhibition of miR-331-3p noticeably increased the luciferase activity with the wild-type 3′-UTR but not the mutant 3′-UTR ( Figure 3G ). Moreover, we analyzed the relationship between ST7L and miR-331-3p expression in 17 pairs of fresh PC tissues and adjacent non-cancerous tissues. Results indicated that the expression of miR-331-3p and ST7L was negatively correlated ( Figure 3H ). The immunohistochemistry analysis performed in the PC tissue microarray contained 20 pairs of PC tissues, and adjacent non-cancerous tissues showed that the expression level of ST7L was lower in PC tissues than in adjacent tissues ( Figure 3I ). Collectively, these data indicate that miR-331-3p negatively regulates the expression of ST7L by directly targeting its 3′ UTR.
Reintroduction of ST7L attenuates the miR-331-3p-induced effects on cell proliferation and EMT-mediated metastasis in vitro
To further investigate whether the effects of miR-331-3p in PC were mediated through ST7L, we transfected miR-331-3p mimics and ST7L expression plasmids into PANC-1 cells. Re-expression of ST7L remarkably suppressed the effects on proliferation ( Figure 4A ), colony formation ( Figure 4B ), wound healing ( Figure 4C ), migration ( Figure 4D ) and invasion ( Figure 4E ) of PANC-1 cells mediated by miR-331-3p. These results showed that the cancer-promoting endpoints of miR-331-3p were partially offset by ST7L reintroduction (Figure 4A-E) . As shown in Figure 4F , overexpression of miR-331-3p suppressed the protein levels of ST7L, which was rescued by increasing ST7L expression. Similar results were observed for the protein levels of E-cadherin, N-cadherin and vimentin ( Figure 4F) . Collectively, these data demonstrated that ST7L reintroduction partially reverses miR-331-3p-mediated cell proliferation and metastasis in vitro.
miR-331-3p antagomir inhibited PC growth and metastasis in vivo
We evaluated the potential of a miR-331-3p antagomir in PC therapeutics using mouse xenografts. PANC-1 cells were injected into BALB/c nude mice subcutaneously, and xenografted tumors were subjected to the miR-331-3p antagomir or the antagomir control for 15 days. The volumes of tumors in mice treated with the miR-331-3p antagomir were markedly smaller than those of mice injected with the control (Figure 5A-C) . Moreover, the weight of tumors was also significantly decreased by the miR-331-3p antagomir ( Figure 5D ). To validate the inhibitory efficiency of the miR-331-3p antagomir in vivo, qRT-PCR was performed to show that the expression of miR-331-3p was notably decreased in tumor tissues treated with the miR-331-3p antagomir ( Figure 5E ). In addition, immunohistochemistry results ( Figure 5F) show that the expression level of Ki-67 was much lower in tumors treated with miR-331-3p antagomir than with the control. Moreover, there was higher expression of E-cadherin, but lower expression of N-cadherin and vimentin in tumors treated with miR-331-3p antagomir than that with the control. ST7L expression was also upregulated by the miR-331-3p antagomir treatment. These findings indicated that miR-331-3p inhibition in tumors reduces PC tumor growth and metastasis through ST7L upregulation.
Discussion
Alterations in miRNA expression contribute to the pathogenesis of many human malignancies. Recently, more and more evidences have supported that miRNAs function as oncogenes or tumor suppressors (24) . It has been reported that miR-200a cooperates with Ras to enhance malignant transformation of an immortalized human epithelial cell line (25) . Our previous research has demonstrated that miR-301a is upregulated in PC and elevate NF-κB activation (26) . In this study, we show that miR-331-3p is upregulated both in PC cell lines and in clinical specimens, and higher expression of miR-331-3p is related to advanced stage and distant metastasis of PC patients. Functional studies demonstrate that inhibition of miR-331-3p suppresses PC cell proliferation, colony formation and EMTmediated metastasis in PC cells, whereas these effects are reversed by overexpression of miR-331-3p. These results indicate that miR-331-3p may function as an oncogene and play a pivotal role in promoting PC cell proliferation and metastasis. Low expression and high expression of miR-331-3p was determined by the cut-off values for miR-331-3p, which were defined as the cohort median, and median of age was used as the cut-off values to define the subgroup. We also demonstrate that circulating miR-331-3p may serve as a non-invasive biomarker for PC diagnosis.
To reveal the molecular mechanisms underlying the role of miR-331-3p, we identify ST7L as a novel functional target of miR-331-3p. ST7L is clustered with WNT2B in human chromosome 1p13, while ST7 is clustered with WNT2 in human chromosome 7q31 (27, 28) . Previous studies indicated that chromosomal instability is characteristic of PC, including loss at 1p13.3 ~ p13.2 and gain at 7q31.32 (29) . WNT2 and WNT2B isoform 2 (WNT2B2) are positive regulators of the WNT-β-catenin-TCF signaling pathway, which play important roles in carcinogenesis(28).
ST7L is downregulated in glioma (23). Zhuang et al. (21) report that ST7L suppresses the AKT/GSK3β/β-catenin pathway in HCC cells and is involved in HCC tumorigenesis and metastasis. However, the significance of ST7L in PC is unclear. Our research indicates that ST7L is a novel target gene of miR-331-3p, and reintroduction of ST7L attenuates the protumorigenesis effects of miR-331-3p. Hence, the pathobiological effects of miR-331-3p are at least partially mediated via ST7L suppression. Our mouse xenograft data support that PC tumor growth and metastasis are repressed by miR-331-3p inhibition, which elevates the expression of ST7L. Data were presented as the mean values ± SD of triplicates. *P < 0.05, **P < 0.01, **P < 0.01, ***P < 0.001.
EMT is a biological process that characterized by molecule rearrangement and cellular phenotype alternation (30, 31) . Previous studies have revealed that EMT plays a key role in both physiological and pathological processes, such as tumor growth and invasion (32) . Besides, cells that have undergone EMT share many characteristics with stem cells, including increased drug resistance and complicating systemic therapy for metastatic disease (33, 34) . Loss of epithelial marker E-cadherin and acquisition of mesenchymal markers such as N-cadherin, vimentin and fibronectin, are hallmarks of EMT (32) . A recent report found that miR-34a inhibits PC progression by regulating Snail1-mediated EMT and Notch signaling (35) . In this work, miR-331-3p inhibition leads to upregulation of E-cadherin and downregulation of N-cadherin and vimentin. Conversely, overexpression of miR-331-3p causes opposite effects on these EMT markers, indicating that miR-331-3p contributes to the process of EMT and leads to the progression of PC.
In conclusion, the present study demonstrates that miR-331-3p is upregulated in PC and that miR-331-3p facilitates PC cell proliferation and EMT-mediated metastasis by suppressing ST7L. miR-331-3p may act as an oncogene in PC and serve as a potential diagnostic biomarker and a drug target. control. All data were presented as mean ± SD of three independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001. Supplementary Figures 1-3 can be found at Carcinogenesis online.
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